Bipolar Androgen Therapy in the Management of Prostate Cancer

[madman]

Bipolar Androgen Therapy in the Management of Prostate Cancer - Samuel Denmeade

Samuel Denmeade, Co-Director of the Johns Hopkins Prostate Cancer Program joins Alicia Morgans in a discussion on Bipolar Androgen Therapy (BAT) for prostate cancer. ADT slows prostate cancer’s progress by shutting off testosterone. Eventually, cancer adapts to this new environment and PSA...

www.urotoday.com

Samuel Denmeade, Co-Director of the Johns Hopkins Prostate Cancer Program joins Alicia Morgans in a discussion on Bipolar Androgen Therapy (BAT) for prostate cancer. ADT slows prostate cancer’s progress by shutting off testosterone. Eventually, cancer adapts to this new environment and PSA levels start to rise. The concept of BAT is for men whose prostate cancer has become resistant to standard hormone-blocking therapy. The pair discuss the ideal patient population for this treatment and its benefits suggesting that the physical vitality of patients could be maintained on BAT.

 

[madman]

Prostate Cancer: Bipolar Androgen Therapy (BAT)

Summary Prostate Cancer Lab #56 focuses on Bipolar Androgen Therapy (BAT) as a potential treatment for castration-resistant prostate cancer. The therapy involves alternating between high-dose testosterone injections and the continuation of testosterone-suppressing drugs. BAT has shown positive...

www.excelmale.com